… Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 Study did not meet … 12. “Given the results observed in earlier studies of sepofarsen, the Illuminate trial results are unexpected and …
… Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … based on commercial sales in the US and EU Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on …
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data …
… Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Top-line data now expected to be announced in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the …
Reported rapid, significant and durable improvements in vision at twelve months
Concordant improvement in key secondary outcome measures
The target registration dose of sepofarsen was well-tolerated with a favorable benefit/risk profile
Strengthens confidence
… ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on … will focus on the following core activities related to sepofarsen: In Q3, the Company plans to meet with the EMA and …
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data fro
ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
